Results 171 to 180 of about 4,926,176 (337)

Anticancer Drug Approval in China: From Acceleration of Access to Certainty of Benefits. [PDF]

Health Data Sci
Zhang J.
europepmc   +1 more source

New Drug Approvals Vol. 25(1)

, 2022
Md Akbar Hossain
openalex   +2 more sources

Molecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines

Molecular Oncology, EarlyView.
Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad, Mahmood Hachim, Tom Bertin, Karolina Penderecka, Rifat Hamoudi, Saif Khan, Rui Henrique, Natalie Bergmoser, Manit Arya, Kalle Sipila, Matteo Vietri Rudan, Asif Muneer, Aamir Ahmed   +12 more
wiley   +1 more source

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma [PDF]

, 2013
Michael D. Axelson, Ke Liu, Xiaoping Jiang, Kun He, Jian Wang, Hong Zhao, Dubravka Kufrin, Todd R. Palmby, Zedong Dong, Anne‐Marie Russell, Sarah Pope Miksinski, Patricia Keegan, Richard Pazdur   +12 more
openalex   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source

The Importance of Cost-Effectiveness in New Drug Approval: Stroke Burden and Tenecteplase Efficacy. [PDF]

J Clin Neurol
Kwon HS, Kim BJ.
europepmc   +1 more source

Advances on anticancer new drugs in China and the USA in 2020: from ongoing trial to drug approval. [PDF]

J Natl Cancer Cent, 2021
Huang H, Miao H, Wang J, Wu D, Lei Q, Wang S, Fang H, Tang Y, Li N, Xu B, He J.   +10 more
europepmc   +1 more source

Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals

, 2015
Jing Hao, Rosa Rodríguez-Monguió, Enrique Seoane‐Vazquez   +2 more
openalex   +2 more sources

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

Molecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal   +16 more
wiley   +1 more source

Drug development for leukemia: comprehensive analysis of clinical trials from first report to drug approval. [PDF]

Blood Adv
Tjioe KC, Miranda-Galvis M, Mamouni K, Freitas T, Sharara M, Santellano B, Guillén-Lopez C, Cortes JE.   +7 more
europepmc   +1 more source